Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
This is a Phase I clinical trial evaluating abemaciclib (LY2835219), an inhibitor of cyclin
dependent-kinases 4 and 6 (Cdk 4/6) in children and young adults with newly diagnosed diffuse
intrinsic pontine glioma (DIPG) (Stratum A) and in relapsed/refractory/progressive malignant
brain (Grade III/IV, including DIPG; MBT) and solid tumor (ST) patients (Stratum B).